EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Ana Vavlukis, Marija Vavlukis, Aleksandar Dimovski, Gordana Petrushevska, Aleksandar Eftimov, Sashka Domazetovska, Kristina Mladenovska

Acta Pharmaceutica · 01.06.2022 · 72 (2) · 303-315

DOI: 10.2478/acph-2022-0018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica, online erschienen am 30.12.2021. Verfasst von Ana Vavlukis und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1University Ss Cyril and Methodius Faculty of Pharmacy 1000 Skopje, RN Macedonia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Rosuvastatin Calcium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein ( p = 0.045), and increased vascular endothelial growth factor ( p = 0.004) and epidermal growth factor ( p = 0.009). A multivariate analysis identified total cholesterol ( p = 0.027) and vascular endothelial growth factor ( p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumHumansAnti-Inflammatory AgentsEGF Family of ProteinsHeart Disease Risk FactorsRisk FactorsVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

cardiovascular riskepidermal growth factorrosuvastatinvascular endothelial growth factor

Substanzen

Anti-Inflammatory AgentsEGF Family of ProteinsHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin CalciumVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • 1University Ss Cyril and Methodius Faculty of Pharmacy 1000 Skopje, RN Macedonia.
  • 2University Ss Cyril and Methodius Faculty of Medicine 1000 Skopje, RN Macedonia.

Zitieren

APA

Vavlukis, A., Vavlukis, M., Dimovski, A., Petrushevska, G., Eftimov, A., Domazetovska, S., & Mladenovska, K. (2022). Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk. Acta Pharmaceutica, 72(2), 303-315. https://doi.org/10.2478/acph-2022-0018

Vancouver

Vavlukis A, Vavlukis M, Dimovski A, Petrushevska G, Eftimov A, Domazetovska S, et al. Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk. Acta Pharmaceutica. 2022;72(2):303-315. doi:10.2478/acph-2022-0018

BibTeX
@article{Vavlukis2022,
  author = {Vavlukis, Ana and Vavlukis, Marija and Dimovski, Aleksandar and Petrushevska, Gordana and Eftimov, Aleksandar and Domazetovska, Sashka and Mladenovska, Kristina},
  title = {Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk},
  journal = {Acta Pharmaceutica},
  year = {2022},
  volume = {72},
  number = {2},
  pages = {303--315},
  doi = {10.2478/acph-2022-0018}
}
Kostenlos starten →